CTKB
NASDAQCytek Biosciences Inc.
News · 26 weeks59+367%
2026-03-012026-08-23
Mix3390d
- Insider16(48%)
- Other7(21%)
- SEC Filings7(21%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- SECCytek Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRJury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining FindingFREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek’s favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost
- INSIDERPRESIDENT AND CEO Jiang Wenbin converted options into 120,095 shares and covered exercise/tax liability with 36,269 shares, increasing direct ownership by 2% to 5,561,029 units (SEC Form 4) (for withholding tax)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERChief Financial Officer Mccombe William D. converted options into 35,420 shares and covered exercise/tax liability with 11,904 shares, increasing direct ownership by 21% to 134,693 units (SEC Form 4) to satisfy withholding tax4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Muir Glenn P converted options into 3,086 shares (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Holder Michael converted options into 2,181 shares, increasing direct ownership by 4% to 62,875 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Chin Richard converted options into 6,107 shares, increasing direct ownership by 27% to 28,499 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming converted options into 33,270 shares and covered exercise/tax liability with 8,088 shares, increasing direct ownership by 0.52% to 4,821,870 units (SEC Form 4) (tax withholding)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer, Secretary Feuchtwang Ilan4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
- SECSEC Form 10-Q filed by Cytek Biosciences Inc.10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)
- SECCytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRCytek Biosciences Reports Second Quarter 2026 Financial ResultsFREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the second quarter of 2025Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabling high-resolution 60-color panelsIntroduced Cytek Aurora™ Evo instrument configurations with expanded automation capabilities for highly automated lab environmentsTotal recurring revenue, comprise
- SECSEC Form SCHEDULE 13G filed by Cytek Biosciences Inc.SCHEDULE 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
- PRCytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next gen
- PRCytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer EngagementFREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility designed to support research and development (R&D) while strengthening collaboration and customer engagement. The new site has been renovated to serve as a dedicated hub for innovation and technical excellence. As the sole tenant of the building, Cytek has designed the space to bring together key capabilities under one roof. The facility includes R&D laboratories and dedicated areas for instrument service t
- SECSEC Form 8-K filed by Cytek Biosciences Inc.8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- INSIDERSEC Form 3 filed by new insider Feuchtwang Ilan3 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SECSEC Form 8-K filed by Cytek Biosciences Inc.8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming gifted 135,892 shares, decreasing direct ownership by 3% to 4,796,688 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SECSEC Form 8-K filed by Cytek Biosciences Inc.8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- INSIDERDirector Ball Jack converted options into 43,973 shares, increasing direct ownership by 103% to 86,678 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 4 filed by Director Muir Glenn P4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 3 filed by new insider Muir Glenn P3 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 4 filed by Director Chin Richard4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
CTKB FAQ
6 questionsWhere does CTKB stock trade?
Cytek Biosciences Inc. (CTKB) is listed on NASDAQ.What sector and industry is CTKB in?
Cytek Biosciences Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Cytek Biosciences Inc. go public?
Cytek Biosciences Inc. (CTKB) completed its IPO in 2021.What are analysts saying about CTKB?
Cytek Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $600.00 price target on 2025-12-02. Recent price targets range from $400.00 to $2000.00.What companies are similar to CTKB?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare CTKB side-by-side with any of them on Quantisnow.How can I track CTKB on Quantisnow?
Quantisnow aggregates Cytek Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTKB to receive live email and push alerts on every new disclosure.